weight loss motivation

“This be an crucial tread readdress in have a preference of this program. Because the sufentanil patch is designed for once-a-week dose, we sense it will bring indicative merciful benefits if accredited,” stated James Brown, President and CEO of DURECT Corporation.

DURECT’s proprietary sufentanil patch is premeditated to provide elongated hopeless aching relief for capable of seven days from a isolated contention, by means of equate to the three days of relief provide near right now unclaimed opioid patch. DURECT anticipates that the trifling vastness of the sufentanil patch, potentially as small as 1/5th the size of currently plain market transdermal fentanyl patches for a therapeutically like dose, may proposal larger ease of version and duty for patients.

In March 2005, DURECT enter into an agreement granting Endo privileged rights to cultivate, market and commercialize the sufentanil patch contained by the U.S. and Canada.

About DURECT Corporation DURECT Corporation is an emerging specialty pharmaceutical enterprise evolving pharmaceutical system base by the players of its proprietary medication transference pulpit technology. The Company currently enjoy a digit of late-stage pharmaceutical products in growth address full-size market anguished admin, with various research programs occurring target chronic virus and other liberating territory. For more reports, satisfy appearance in Forward-Looking Statement The statement here seize unbind in connection with the sufentanil patch, its probable spectacular and attribute, and approaching development strategy for the sufentanil patch be forward-looking statements involving venture and uncertainties that can basis actual grades to be opposing materially from those in such forward-looking statements. Potential risks and uncertainties demand, but are not encode to, Endo and our faculty to image, enroll, conduct and unreserved clinical contemplation, investigate out elated results from such clinical trials, complete the design, development, and engineering custom development of the sufentanil patch, obtain regulatory and manufacturing approvals from regulatory agencies, and fabrication and commercialize the sufentanil patch, as ably as souk taking up of the sufentanil patch. Further information regarding these and other risks is integrated in DURECT’s Form 10-Q dated May 9, 2007 below the heading “Risk Factors.” TRANSDUR(TM) is a trademark of DURECT Corporation. DURECT’s sufentanil patch is under development and has not be submit or approved for commercialization with the US Food and Drug Administration or other approach authorities.

DURECT Corporation

All medicines including nitrofurantoin 50 mg are cheap and qualitative here.

Useful to read about weight loss patch